DelveInsight’s “Inflammatory Bowel Disease Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Inflammatory Bowel Disease Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Inflammatory Bowel Disease Market Size

Key Takeaways from the Inflammatory Bowel Disease Market Report

• In April 2025, Morphic Therapeutics Inc. announced a phase 2 study to evaluate the efficacy and safety of induction therapy with 2 active dose regimens of MORF-057 versus matching placebo in adult study participants with moderately to severely active CD. After completion of the 14-week Induction Period, all participants will receive open-label MORF-057 during the 38-week Maintenance Period. All participants who complete the full 52-week Treatment Period will also have the opportunity to continue treatment in a 52-week Maintenance Extension.
• In April 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in participants with moderately to severely active Ulcerative Colitis (UC) and as subcutaneous (SC) administration in maintenance study in participants with moderately to severely active Ulcerative Colitis (UC) who have demonstrated a clinical response to Induction treatment with IV ustekinumab.
• The US accounted for ~50% of the total Inflammatory Bowel Disease Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase during the forecast period.
• In the US, the moderate to severe cases were found to be higher than the mild cases of Inflammatory Bowel Disease in 2023.
• In the US, the 18-44 years age segment accounted for the highest number of cases of Inflammatory Bowel Disease in 2023.
• Among EU4 and the UK, Germany accounted for the highest prevalent cases of Inflammatory Bowel Disease , followed by the UK in 2023.
• The leading Inflammatory Bowel Disease Companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie and others.
• Promising Inflammatory Bowel Disease Pipeline Therapies such as Mirikizumab, RHB-104, ZEPOSIA® (ozanimod; RPC1063), and others.

Stay ahead in the competitive landscape of the Inflammatory Bowel Disease Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Inflammatory Bowel Disease Treatment Market Size

Inflammatory Bowel Disease Epidemiology Segmentation in the 7MM

• Total Inflammatory Bowel Disease Diagnosed Prevalent Cases
• Inflammatory Bowel Disease Type-specific Cases
• Inflammatory Bowel Disease Severity-specific Cases
• Inflammatory Bowel Disease Age-specific Cases
• Inflammatory Bowel Disease Treatable cases

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Prevalence

Inflammatory Bowel Disease Marketed Drugs

• RINVOQ (upadacitinib): AbbVie

RINVOQ is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. In March 2022, the US FDA approved RINVOQ for the treatment of adults with moderately to severely active ulcerative colitis.

STELARA (ustekinumab): Janssen Pharmaceuticals

STELARA is a human monoclonal antibody. It mediates the body’s T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). IL-12 and IL-23 are cytokines that modulate lymphocyte function and have been implicated in the pathogenesis of inflammatory diseases. In September 2016, the US FDA approved STELARA for the treatment of adults with moderately to severely active Crohn’s disease.

Inflammatory Bowel Disease Emerging Drugs

• Obefazimod: Abivax

Obefazimod is an orally available, small molecule binder of the cap-binding complex (CBC) 80/20 being developed by Abivax. It is being investigated in the Phase III (ABTECT) clinical trial for patients with moderately to severely active ulcerative colitis and the Phase II trial for patients with Crohn’s disease. The company is anticipating the enrolment of the last patient in the ABTECT induction trial in the fourth quarter of 2024.

• MORF-057: Morphic Therapeutic

MORF-057 is a selective, oral small molecule inhibitor of the α4β7 integrin in development to treat patients suffering from inflammatory bowel disease and is currently in Phase IIb (EMERALD-2) clinical trial. The company is anticipating results in the first half of 2025. The EMERALD-1 Phase IIa study achieved its primary endpoint, demonstrated consistent, clinically meaningful improvements across secondary and exploratory measures, and was well tolerated with no safety signal observed.

Discover the future of Inflammatory Bowel Disease Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Inflammatory Bowel Disease Market Drivers and Barriers

Inflammatory Bowel Disease Companies

Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie and others.

Inflammatory Bowel Disease Market Outlook

Over the last decade, the introduction of several key therapies has shaped the management of inflammatory bowel disease. Drugs like HUMIRA (AbbVie), REMICADE (Janssen), and ENTYVIO (Takeda) have helped patients achieve meaningful endpoints of clinical remission and mucosal healing. They have also helped many patients avoid colectomy, an outcome once much more common before the expansion of the IBD medicine cabinet. Dual-targeted therapy shows promise in treating patients with refractory IBD. It may provide new opportunities to improve the patient’s quality of life and long-term prognosis, making it possible to break through the current ceiling of IBD treatment. Moreover, in recent years, the success of bispecific antibodies in tumor management has provided new ideas for treating immune diseases including IBD.

Explore the dynamics of the Inflammatory Bowel Disease Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Inflammatory Bowel Disease Ongoing Clinical Trials Analysis

Scope of the Inflammatory Bowel Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Inflammatory Bowel Disease Companies- Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie and others.
• Inflammatory Bowel Disease Pipeline Therapies- Mirikizumab, RHB-104, ZEPOSIA® (ozanimod; RPC1063), and others.
• Inflammatory Bowel Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement

Table of Content

1. Key insights

2. Inflammatory Bowel Disease Market Report Introduction

3. Inflammatory Bowel Disease Executive Summary

4. Inflammatory Bowel Disease (IBD): Market Overview at a Glance

5. Key Events

6. Inflammatory Bowel Disease Epidemiology and Market Forecast Methodology

7. Inflammatory Bowel Disease Market Disease Background and Overview

8. Inflammatory Bowel Disease Treatment

9. Inflammatory Bowel Disease Epidemiology and Patient Population

10. Inflammatory Bowel Disease Patient Journey

11. Inflammatory Bowel Disease Marketed Products

12. Inflammatory Bowel Disease Emerging Therapies

13. Inflammatory Bowel Disease (IBD): Seven Major Market Analysis

14. Inflammatory Bowel Disease SWOT Analysis

15. Inflammatory Bowel Disease Unmet Needs

16. Inflammatory Bowel Disease KOL Views

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market